JPMorgan Chase & Co. Boosts Qiagen (NYSE:QGEN) Price Target to $50.00

Qiagen (NYSE:QGEN) had its target price hoisted by stock analysts at JPMorgan Chase & Co. from $45.00 to $50.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 17.76% from the company’s previous close.

QGEN has been the topic of several other reports. Weiss Ratings cut shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $43.00 price target on shares of Qiagen in a report on Thursday, April 30th. Robert W. Baird set a $43.00 price target on Qiagen and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Stifel Nicolaus set a $40.00 price objective on Qiagen in a report on Friday. Finally, Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $43.34.

Qiagen Stock Performance

Shares of NYSE:QGEN traded up $0.73 on Friday, hitting $42.46. The company had a trading volume of 1,204,113 shares, compared to its average volume of 2,433,088. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of 21.76, a P/E/G ratio of 4.19 and a beta of 0.63. The stock has a 50 day moving average price of $39.32 and a 200 day moving average price of $41.69. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The company’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts expect that Qiagen will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Institutional investors have recently made changes to their positions in the stock. Boston Partners bought a new stake in shares of Qiagen during the 3rd quarter worth approximately $179,450,000. Norges Bank bought a new position in Qiagen in the fourth quarter valued at approximately $166,500,000. Dimensional Fund Advisors LP bought a new position in Qiagen in the third quarter valued at approximately $58,079,000. Price T Rowe Associates Inc. MD raised its position in Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Finally, Deutsche Bank AG raised its position in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after purchasing an additional 697,342 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.